Hike Medical raised $22.5 million in seed and Series A funding. Here is what investors are betting O&P workflow AI is worth.

Hike Medical, which describes itself as a medical device company and artificial intelligence platform serving the orthotics, prosthetics, durable medical equipment, and podiatry industries, has raised $22.5 million in combined seed and Series A funding, per reporting in The O&P EDGE.

That is the announcement. The amount is substantial for a company working in a clinical specialty as narrow as O&P. Understanding why an AI platform in this space attracts that level of capital requires spending a few minutes on the problem it is selling against.

The administrative burden that draws investors

O&P billing is not like most medical billing. The L-code system, the procedure-code framework used to classify orthotic and prosthetic devices for Medicare and Medicaid reimbursement, pairs device codes with documentation requirements that are unusually specific. A lower-limb prosthetic for a Medicare beneficiary does not simply need a prescription. It requires functional level documentation, a classification of the patient’s demonstrated or expected mobility as K1 through K4, along with clinical notes, functional assessments, and evidence of medical necessity linked to that classification. Higher-tier devices require stronger functional documentation. The documentation has to survive both a claim review and, potentially, a post-payment audit.

CMS substantially tightened scrutiny on lower-limb prosthetic claims in the early 2010s. Audit contractors working under the Targeted, Probe, and Educate program have consistently found O&P among the specialty areas with elevated error rates. For a small practice (two or three clinicians, which is the modal O&P clinic structure) the staff hours consumed by prior authorization submissions, documentation formatting, and denial rework are not trivial. They are also hours not spent fitting devices.

That combination of high per-claim complexity, regulatory audit exposure, and thin clinical staffing describes exactly the pressure point where AI workflow tools have a value proposition. If a platform can reduce denial rates, accelerate prior authorization turnaround, or surface the documentation gaps before a claim is submitted, the dollar value to a practice is real and calculable.

What $22.5 million is being used for

Combined seed and Series A disclosures, rather than a single-round announcement, sometimes indicate that a company raised an early round without fanfare and is now choosing to publicize total capital in connection with the larger raise. Whatever the sequencing, $22.5 million is enough to build a material engineering team, hire clinical and regulatory staff, and fund a go-to-market effort over a multi-year runway.

In a sector as specialized as O&P, reaching customers requires a sales function that understands clinical workflow, not just enterprise software sales. Practices are small, decisions are often made by working clinicians rather than procurement departments, and the product has to integrate with existing billing and documentation systems. Building that sales motion while maintaining the product and serving early adopters requires sustained capital investment.

Clinical validation is the other significant cost. An AI platform that wants to make auditable claims about outcome improvement, rather than purely efficiency claims, needs data. Peer-reviewed evidence that a tool reduces denial rates, improves documentation completeness, or shortens prior authorization cycles requires study design, data collection, and publication. That work takes years and money. Companies that skip it remain in the marketing-claim category; companies that do it can engage with payers, accreditation bodies, and clinical guidelines in a different register.

The two weeks before the raise

Two weeks before the funding disclosure, Hike Medical announced the hire of Chad Duncan, PhD, CRC, CPO, MSO, as clinical director. Duncan is a board-certified practitioner in both prosthetics and orthotics, holds a separate certification in rehabilitation counseling, and has doctoral-level research training. That hire was reported here in August.

The sequencing (credential the clinical leadership, then announce the capital) is consistent with a company preparing to expand from an early customer base into a broader market and needing both legitimacy and runway to do it. A clinical director with CPO credentials gives the company standing in conversations with O&P practitioners that a non-clinical hire would not. The capital gives it the time to have those conversations at scale.

Whether the two announcements are strategically coordinated or coincidentally timed, the effect is a company that in two weeks has positioned itself with clinical credibility and financial capacity. That pairing is intentional in how it reads to the O&P market, even if the individual decisions behind each announcement were separate.

What this does not settle

A capital raise does not tell us that Hike Medical’s platform produces the outcomes it implies. It does not tell us where, specifically, its tools operate in the clinical workflow: whether they assist with documentation formatting after a device decision is made, or whether they surface recommendations at an earlier stage in the encounter. That distinction matters for practitioners evaluating adoption and for patients who may not know an AI system influenced the paperwork that determined their coverage.

The raise also does not tell us what evidence Hike Medical has published or intends to publish about its platform’s performance. $22.5 million is an investor’s bet on the size of the problem and the company’s capacity to address it. It is not peer-reviewed evidence that the address is working.

For O&P practices weighing adoption: the relevant questions remain how the tool integrates with existing documentation systems, what the evidence basis for its outputs looks like, where liability sits when a claim is submitted based on AI-assisted documentation, and what the company’s terms are for data generated by clinical encounters.

For patients: AI tools in O&P are currently most consequential at the billing and documentation layer. They affect the administrative processing of a care decision more than the clinical decision itself. The fitting conversation and the functional assessment still happen in a room with a clinician. What AI can influence is whether the paperwork describing that encounter is complete enough to survive a payer review, and in a system where prior authorization denial can delay or prevent device access, that is not an irrelevant influence.

---

Amputee News does not provide individualized medical, billing, or coverage advice. References to company funding and platform capabilities are based on trade publication reporting and do not constitute endorsement of any product or service.